Lactose-Free Milk Protein-Based Infant Formula: Impact on Growth and Gastrointestinal Tolerance in Infants
Lactose-Free Milk Protein-Based Infant Formula: Impact on Growth and Gastrointestinal Tolerance in Infants
复制标题
DOI：
10.1177/0009922810390511
复制
发表时间：
2011-04
影响因子：
1.6
通讯作者：
J. Lasekan;J. Jacobs;K. Reisinger;M. Montalto;M. Frantz;M. Blatter
中科院分区：
文献类型：
--
作者：
J. Lasekan;J. Jacobs;K. Reisinger;M. Montalto;M. Frantz;M. Blatter
乳糖是人乳和标准乳基配方奶粉中的主要碳水化合物，为婴儿的生长提供能量。在美国，无乳糖乳蛋白基婴儿配方奶粉的使用有所增加。然而，其对婴儿生长、安全性和胃肠道耐受性影响的临床研究有限。因此，在健康的正常足月婴儿中进行了一项前瞻性、盲法、随机临床试验，喂养实验性无乳糖乳蛋白配方奶粉（NoLAC; n = 63）与标准商业含乳糖乳配方奶粉（LAC; n = 65），持续112天。两组的生长（体重、身长和头围）相似且正常（体重增加：NoLAC = 31.1 ± 0.9 g/天，LAC = 29.4 ± 0.9 g/天，平均值± SEM; P = 0.895）。两组的血清生化指标均在婴儿的正常参考范围内。两组的耐受性相当，但NoLAC组的粪便更软，呕吐更少。因此，该研究表明，乳基配方奶粉中不含乳糖不会对足月婴儿的正常生长产生不利影响。
Lactose, the major carbohydrate in human milk and standard milk—based formulas, provides energy for growth in infants. The use of lactose-free milk protein—based infant formulas has increased in the United States. However, clinical studies of their impact on growth, safety, and gastrointestinal tolerance in infants are limited. Thus, a prospective, blinded, randomized clinical trial was conducted in healthy, normal-term infants fed an experimental lactose-free milk protein—based formula (NoLAC; n = 63) versus a standard commercial lactose-containing milk-based formula (LAC; n = 65) for 112 days. Growth (weight, length, and head circumference) was similar and normal in both groups (weight gain: NoLAC = 31.1 ± 0.9 g/day, LAC = 29.4 ± 0.9 g/day, mean ± SEM; P = .895). Serum biochemistries for both groups were within infants’ normal reference ranges. Both groups had comparable tolerance but the NoLAC group had softer stools and lower spit-ups. Thus, the study suggests that absence of lactose in milk-based formula does not adversely affect normal growth in term infants.